Summary of Abs targeting CD40/CD40L interaction
| Ab | Properties | Clinical trials* | Results | References |
|---|---|---|---|---|
| Dapirolizumab pegol (CDP7657) | Anti-CD40L Fab | Phase 2 trial for SLE | Improved clinical outcomes of the disease Well-tolerated Did not reach the primary endpoint of dose-response in phase 2b | [114–116] |
| VIB4920 | CD40L binding protein composed of 2 Tn3 proteins fused to serum albumin | Phase 1b for RA | Decreased disease activity Safe without serious adverse effects | [119, 120] |
| Iscalimab (CFZ533) | Fully human antagonistic anti-CD40 monoclonal IgG1 Abs | Phase 2 for: Kidney transplant-SS | Safer than tacrolimus in regards to nephrotoxicity and infectious complications but less efficacious in preventing transplant rejection Efficacious for SS | [121–124] |
| BI-655064 | Humanized antagonistic anti-CD40 monoclonal IgG1 Ab | Phase 2 for RA | Good add-on to methotrexate Improved clinical outcomes Reduced RF auto-Ab titers | [126] |
This table presents information on the different molecules made to inhibit the CD40/CD40L interaction. Inhibiting this interaction greatly affects the immune response and thus it has been used in clinical trials against autoimmune diseases and transplant rejection. *: this list is not comprehensive. SS: Sjogren’s syndrome; RF: rheumatoid factor